Home Blog Page 1306

diaTribe Convenes International Consensus to Guide Diabetes Technology Use During Pregnancy

Expert recommendations provide crucial guidance to leverage CGM and AID during pregnancy.

SAN FRANCISCO, Jan. 13, 2026 /PRNewswire/ — The diaTribe Foundation announces the publication of the first international consensus statement on the use of continuous glucose monitoring (CGM) and automated insulin delivery (AID) during pregnancy. Published in The Lancet Diabetes & Endocrinology, the document aims to standardize care, improve outcomes, and ease the daily burden of managing type 1 (T1D), type 2 (T2D), and gestational diabetes (GDM) during pregnancy.

Managing diabetes is exceptionally challenging during pregnancy due to hormonal shifts and narrow glucose targets. As CGM and AID become standard of care in diabetes for their ability to improve management, many enter pregnancy already relying on these technologies or adopt them to help navigate this demanding time.

Despite growing use, application of technology has remained disjointed in pregnancy due to a lack of detailed clinical guidance, particularly for T2D and GDM. “Application of Continuous Glucose Monitoring and Automated Insulin Delivery Technologies for Pregnant Women with Type 1 Diabetes, Type 2 Diabetes or Gestational Diabetes Mellitus” was developed by experts across six continents to address this gap.

“It is absolutely possible to have a safe and healthy pregnancy with diabetes, and technologies can help—but these tools are often underutilized due to limited research, few devices approved for use in pregnancy, and a lack of clear guidance,” said Dr. Katrien Benhalima, endocrinologist and chair of the expert author group. “Publishing this consensus is a key step to ensuring that maternal healthcare for people with diabetes continues to improve as technologies evolve.”

The paper provides 14 specific recommendations, including:

  • Guidance on picking AID systems and adapting settings to meet pregnancy-specific physiological needs, including detailed charts with device-specific recommendations
  • Considerations for technology use during preconception, pregnancy, labor and delivery, and the immediate postpartum period
  • CGM time in range targets specifically for T2D and GDM, expanding upon previous standards set for T1D.

The consensus aims to support key members of the pregnancy care team who may be less familiar with diabetes technologies, including primary care and obstetrics providers, through recommendations based on the latest evidence and clinical experience. By confirming these technologies can be safely used during pregnancy, the authors also hope to increase device access and user confidence.

This initiative was led by The diaTribe Foundation and strengthened by input from 25 leading global bodies, including the American College of Obstetricians and Gynecologists, Breakthrough T1D, European Association for the Study of Diabetes, and World Organization of Family Doctors.

The diaTribe Foundation is dedicated to improving the lives of people with diabetes and advocating for action. We ensure that people have the resources and education needed to thrive with diabetes, bring people with diabetes to the conversation on regulatory issues, connect the field and the diabetes community, and change the narrative around diabetes.

Endorsing organizations:
ADJ Diabetes Brazil
Advanced Technologies & Treatments for Diabetes
American Association of Clinical Endocrinology
American College of Diabetology
American Pharmacists Association
Association of Diabetes Care & Education Specialists
Australasian Diabetes in Pregnancy Society
Australian Diabetes Society
Australian Diabetes Educators Association
Brazilian Diabetes Society
Breakthrough T1D
Centre for Chronic Disease Control (India)
Diabetes Australia
Diabetes India
European Association for the Study of Diabetes
European Board and College of Obstetrics and Gynaecology
Indian College of Obstetricians and Gynaecologists
International Association of Diabetes and Pregnancy Study Groups
International Diabetes Federation
International Federation of Gynaecology and Obstetrics
Japan Diabetes Society
Research Society for the Study of Diabetes India
Society for Obstetric Medicine India
World Organization of Family Doctors

Supported by the American College of Obstetricians and Gynecologists

NVISAGE Technologies to Present Complete Golf Launch Monitor Lineup at PGA Show 2026

CHICAGO, Jan. 13, 2026 /PRNewswire/ — NVISAGE Technologies, a U.S.-based leader in next-generation golf technology, will showcase its full portfolio of golf launch monitors at PGA Show 2026, the industry’s most influential golf trade event. The exhibition will take place from January 21–23, 2026, in Orlando, Florida, where attendees can explore NVISAGE’s innovative golf technology at booth 1515.

NEO-E Launch Monitor
NEO-E Launch Monitor

Founded in 2023 and headquartered in Illinois, NVISAGE Technologies has quickly established itself as a trusted name in indoor and outdoor golf solutions. The company’s mission is to make advanced swing analytics more accessible to golfers of all experience levels. Each NVISAGE product is built on precision engineering and user-friendly design, providing reliable data that empowers players to improve their game with confidence.

At this year’s PGA Show, NVISAGE will unveil its complete lineup of launch monitors—ranging from entry-level options to advanced models for professionals—alongside its powerful golf analytics software, MURLIE. Every device is designed and manufactured in-house, ensuring uncompromising quality and consistency. NVISAGE’s launch monitors deliver instant, high-accuracy feedback through integrated processing systems, removing the need for external computers or complex setups.

Exhibit Highlights:

  • N1 Launch Monitor: An affordable, overhead model featuring a 16″ x 20″ hitting zone and dual-camera system. Lightweight and easy to install, the N1 is perfect for beginners or golfers seeking a simple yet reliable solution for home or indoor use.
  • N2 Launch Monitor: A high-end overhead model tailored for professional training. With a 32″ x 24″ hitting zone and triple-camera system, the N2 delivers precise ball, club, and flight data. It offers comprehensive analytics for serious players looking to refine their performance.
  • NEO-E Launch Monitor: Built for golfers who value portability, the NEO-E is ideal for both indoors and outdoors. The device is IP65-rated for water and dust resistance, ensuring durability in any environment. Its five-hour battery life and integrated processing make it a dependable companion for practice sessions on the move.
  • NEO-T Launch Monitor: Designed for coaching environments and driving ranges, the NEO-T is a floor-mounted system with a 16″ x 16″ hitting zone. A 10.1″ touchscreen display provides quick access to data and controls, offering a streamlined experience for instructors and players alike.
  • NEO-i Launch Monitor: The newest addition to the NVISAGE family, the NEO-i is an entry-level floor model created for young players and beginners. Compact, intuitive, and affordable, it provides essential ball, club, and swing data to help new golfers build confidence and technique.
  • MURLIE Software: Compatible with all NVISAGE devices, MURLIE serves as the core software platform for swing analysis and simulation. It features four modes—Shot Analysis, Driving Range, Putting, and Record Mode—and supports up to four user profiles. MURLIE also integrates seamlessly with popular third-party software such as E6 Connect and GSPro.

Recognized as the premier global event for the golf industry, the PGA Show brings together thousands of golf professionals, brands, and enthusiasts from around the world. NVISAGE Technologies’ participation highlights its continued commitment to innovation, precision, and accessibility—bringing cutting-edge golf technology to players everywhere, from beginners to seasoned pros.

About NVISAGE Technologies

At NVISAGE Technologies, we value simplicity and precision. Our technology-driven entertainment solutions prioritize an intuitive experience and pave the way for a new era of accessible and high-quality indoor and outdoor golf, ensuring that enthusiasts can enjoy the sport they love with unparalleled convenience and innovation. For more information, please visit nvisagetech.com.

 

Delta Intelligent Building Technologies Receives the 2025 Global Integrated Smart Buildings Solutions Competitive Strategy Leadership Recognition

Frost & Sullivan honors the company for its leadership in technology integration, collaboration, and innovation across the smart buildings ecosystem

SAN ANTONIO, Jan. 12, 2026 /PRNewswire/ — Frost & Sullivan is pleased to announce that Delta Intelligent Building Technologies has earned the 2025 Global Competitive Strategy Leadership Recognition in the integrated smart buildings solutions industry for its outstanding achievements in openness, reliability, intelligent automation, and forward-looking innovation. This recognition highlights Delta Intelligent Building Technologies’ consistent leadership in driving measurable outcomes, strengthening its market position, and delivering customer-centric advancements in an evolving competitive landscape.

Frost & Sullivan evaluates companies through a rigorous benchmarking process across two core dimensions: strategy effectiveness and strategy execution. Delta Intelligent Building Technologies excelled in both, demonstrating its ability to align strategic initiatives with market demand while executing them with efficiency, consistency, and scale.

Guided by a long-term growth strategy focused on building automation, smart infrastructure, and innovation, Delta Intelligent Building Technologies has shown its ability to adapt and lead in a rapidly evolving landscape. The company’s strategic agility and sustained investment in open architecture, reliable performance, and intelligent automation have enabled it to scale effectively across global markets.

Innovation remains central to Delta Intelligent Building Technologies’ approach. Its suite of integrated smart building solutions addresses the full spectrum of building automation, energy management, and Internet of Things integration, offering transparency, flexibility, and high performance through open-protocol, backward-compatible platforms. “Our ability to transform cutting-edge technologies such as AI into industry-changing solutions for our customers is exactly what fuels this innovation and what continues to set Delta apart,” said John Nicholls, President at Delta Intelligent Building Technologies.

Delta Intelligent Building Technologies’ unwavering commitment to customer experience further strengthens its position in the market. “Multi-decade client relationships showcase satisfaction and enduring trust,” according to Melvin Leong, Senior Director at Frost & Sullivan. By emphasizing openness, reliability, and intelligent automation, the company helps organizations streamline operations, enhance energy efficiency, and achieve long-term system resilience. Its partner-led delivery model and focus on global collaboration ensure consistent service quality, while its customer-first values promote enduring trust—a hallmark of its decades-long relationships worldwide.

Frost & Sullivan commends Delta Intelligent Building Technologies for setting a high standard in competitive strategy, execution, and market responsiveness. The company’s vision, innovation pipeline, and dedication to technology integration are shaping the future of integrated smart buildings and driving tangible results at scale.

Each year, Frost & Sullivan presents the Competitive Strategy Leadership Recognition to a company that demonstrates outstanding strategy development and implementation, resulting in measurable improvements in market share, customer satisfaction, and competitive positioning. The honor recognizes forward-thinking organizations reshaping their industries through innovation and growth excellence.

Frost & Sullivan Best Practices Recognition

Frost & Sullivan’s Best Practices Recognitions honor companies across regional and global markets that exhibit exceptional achievement and consistent excellence in areas such as leadership, technological innovation, customer experience, and strategic product development. Each recognition is the result of a rigorous analytical process in which Frost & Sullivan industry experts benchmark performance through comprehensive interviews, deep-dive analysis, and extensive secondary research. The goal is to identify true best-in-class organizations that are driving transformative growth and setting new industry standards.
Contact us: Start the discussion.

Contact
Camila Tinajero
E: camila.tinajero@frost.com 

About Delta Intelligent Building Technologies

Based in Metro Vancouver, Canada, Delta Intelligent Building Technologies manufactures smart, user-friendly control solutions for commercial, healthcare, hospitality, education, and data center buildings. As part of Delta Electronics, Delta Intelligent Building Technologies is committed to advancing sustainable intelligent building technologies. 

Contact:
Pamela Gamiz Valero
E: pvalero@deltacontrols.com 

Field Medical to Present at the 44th Annual J.P. Morgan Healthcare Conference

CARDIFF-BY-THE-SEA, Calif., Jan. 12, 2026 /PRNewswire/ — Field Medical Inc., a clinical-stage medical technology company advancing a versatile, next-generation pulsed field ablation (PFA) platform designed to support both ventricular tachycardia (VT) and atrial fibrillation (AF) ablation, today announced that its founder, Steven Mickelsen, MD, will present at the 44th annual J.P. Morgan Healthcare Conference on Thursday, Jan. 15, 2026, at 10 a.m. PT at The Westin St. Francis in San Francisco.

The FieldForce™ Ablation System by Field Medical: This next-generation PFA system is designed for transmural lesion creation, offering a novel approach to VT ablation.
The FieldForce™ Ablation System by Field Medical: This next-generation PFA system is designed for transmural lesion creation, offering a novel approach to VT ablation.

The presentation will feature a company overview, including the FieldForce™ PFA platform, clinical progress in VT, the Field-PULSE AF study, and plans for the upcoming pivotal VT trial.

Field Medical’s leadership team will be available for meetings during the conference. To request a meeting, please email ir@fieldmedicalinc.com.

About Field Medical® Inc.
Founded in 2022, Field Medical is a clinical-stage medical technology company committed to advancing pulsed field ablation (PFA) solutions for complex cardiac arrhythmias. Its FieldForce™ Ablation System integrates a focal catheter design with proprietary FieldBending™ energy designed to safely deliver efficient, precise ablation with the goal of improving outcomes in ventricular and atrial arrhythmia treatment. In 2024, Field Medical earned Breakthrough Device Designation and gained entry into the FDA TAP Pilot Program for its ventricular tachycardia indication. In October 2025, the VCAS trial was published in Circulation.

For more information, visit www.fieldmedicalinc.com and follow us on LinkedIn, X and YouTube.

The FieldForce™ Ablation System is an investigational device and is limited by federal (or U.S.) law to investigational use.

Contacts
Media
Holly Windler
619.929.1275
media@fieldmedicalinc.com

Investor Relations
ir@fieldmedicalinc.com

 

ESD Alliance Reports Electronic System Design Industry Posts $5.6 Billion in Revenue in Q3 2025

APAC Region Reported Double-Digit Year-over-Year Revenue Increase

MILPITAS, Calif., Jan. 12, 2026 /PRNewswire/ — Electronic System Design (ESD) industry revenue increased 8.8% to $5,566.4 million in the third quarter of 2025 from the $5,114.5 million registered in the third quarter of 2024, the ESD Alliance, a SEMI Technology Community, announced today in its latest Electronic Design Market Data (EDMD) report. The four-quarter moving average rose 10.4%, based on a comparison of the most recent four quarters to the prior four.

“The electronic design automation (EDA) industry continues to report strong year-over-year revenue growth in Q3 2025,” said Walden C. Rhines, Executive Sponsor of the SEMI Electronic Design Market Data report. “All product categories reported increases, with Semiconductor IP (SIP) and Services showing double digit gains. Geographic regions including Americas, EMEA, and APAC reported growth in Q3, with a double digit increase in APAC.”

The companies tracked in the EDMD report employed 73,185 people globally in Q3 2025, a 17.3% increase over the Q3 2024 headcount of 62,417 and up 0.9% compared to Q2 2025.

The quarterly EDMD report contains detailed revenue information within the following category and geographic breakdowns.

Revenue by Product and Application Category – Year-Over-Year Change

  • Computer-Aided Engineering (CAE) revenue increased 9.1% to $2,097.8 million. The four-quarter CAE moving average increased 11.6%.
  • IC Physical Design and Verification revenue increased 1.3% to $865.4 million. The four-quarter moving average for the category decreased 1.2%.
  • Printed Circuit Board and Multi-Chip Module (PCB and MCM) revenue rose 3.4% to $466.2 million. The four-quarter moving average for PCB and MCM rose 8.1%.
  • Semiconductor Intellectual Property (SIP) revenue increased 13.6% to $1,915.7 million. The four-quarter SIP moving average rose 14.8%.
  • Services revenue increased 10.2% to $221.4 million. The four-quarter Services moving average rose 13.7%.

Revenue by Region – Year-Over-Year Change

  • The Americas, the largest reporting region by revenue, procured $2,402.2 million of electronic system design products and services in Q3 2025, a 3.4% increase. The four-quarter moving average for the Americas rose 10.3%.
  • Europe, Middle East, and Africa(EMEA) procured $675.1 million of electronic system design products and services in Q3 2025, a 4.6% increase. The four-quarter moving average for EMEA grew 7.6%.
  • Japan’s procurement of electronic system design products and services decreased 11.5% to $264.0 million in Q3 2025. The four-quarter moving average for Japan increased 2.4%.
  • Asia Pacific (APAC) procured $2,223.0 million of electronic system design products and services in Q3 2025, a 20.5% increase. The four-quarter moving average for APAC grew 12.8%.

About the EDMD Report
The ESD Alliance Electronic Design Market Data (formerly the Market Statistics Service) report presents Electronic Design Automation (EDA), SIP and Services industry revenue data quarterly. Both public and private companies contribute data to the report available from SEMI. Each quarterly report is published approximately three months after quarter close. EDMD report data is segmented as follows:

  • Revenue by product category (CAE, IC Physical Design and Verification, SIP, PCB/MCM Layout, and Services) including numerous detailed sub-categories
  • Revenue by geographic region (Americas, EMEA, Japan and APAC)
  • Total employment at participating companies

For information about SEMI market research reports, visit the SEMI Market Research Reports and Databases Catalog.

About the Electronic System Design Alliance
The Electronic System Design (ESD) Alliance, a SEMI Technology Community, is the central voice to communicate and promote the value of the semiconductor design ecosystem as a vital component of the global electronics industry. As an international association of companies providing goods and services throughout the semiconductor design ecosystem, it is a forum to address technical, marketing, economic and legislative issues affecting the entire industry. For more information about the ESD Alliance, visit http://esd-alliance.org.

Follow the ESD Alliance

About SEMI
SEMI® is the global industry association connecting over 3,000 member companies and 1.5 million professionals worldwide across the semiconductor and electronics design and manufacturing supply chain. We accelerate member collaboration on solutions to top industry challenges through Advocacy, Workforce Development, Sustainability, Supply Chain Management and other programs. Our SEMICON® expositions and events, technology communities, standards and market intelligence help advance our members’ business growth and innovations in design, devices, equipment, materials, services and software, enabling smarter, faster, more secure electronics. Visit www.semi.org, contact a regional office, and connect with SEMI on LinkedIn and X to learn more.

The information supplied by the ESD Alliance is believed to be accurate and reliable, but the ESD Alliance assumes no responsibility for any errors that may appear in this document. All trademarks and registered trademarks are the property of their respective owners.

Association Contacts

Paul Cohen
Phone: 978-769-2106
Email: pcohen@semi.org

Stephanie Quinn/Kiterocket (Media Inquiries)
Phone: 1-480-316-8370
Email: squinn@kiterocket.com

Suvoda sets new standard for streamlined patient and site experience in clinical trials

CONSHOHOCKEN, Pa., Jan. 12, 2026 /PRNewswire/ — Suvoda, a clinical trial technology company, took decisive steps in 2025 toward a more connected and streamlined clinical trial experience for both patients and sites. The company’s merger with Greenphire marked a pivotal moment in that journey, strengthening Suvoda’s ability to tackle persistent trial operational challenges with a more unified approach. Together with continued product innovation and deployment of AI tools, Suvoda closed the year with growing momentum toward a single, cohesive ecosystem that reduces complexity across the clinical trial lifecycle.

“The last twelve months marked an important step forward for Suvoda,” said Jagath Wanninayake, CEO of Suvoda. “Our teams worked with care and intention as we brought two strong companies together and delivered new capabilities that reflect what patients and sites actually need. As we enter 2026, we’re focused on helping sponsors and sites navigate their trials with clarity while giving patients a smoother, more supportive experience.”

Making the patient journey easier

A defining milestone of the year was the launch of Suvoda’s patient app, a clear demonstration of how a unified platform can meaningfully improve the clinical trial experience for patients. The app brings eCOA questionnaires, patient payments, reminders, and visit scheduling into one consumer-grade interface that patients can use on their own devices. This advancement helps participants stay engaged while easing the administrative load for busy sites.

Harnessing AI to alleviate administrative burden in clinical trials

Suvoda also simplified how study teams access critical information with Sofia, an AI assistant currently deployed in Suvoda IRT with platform expansion in the future. Sofia helps users ask questions and get answers with a generative AI tool, replacing multi-step navigation with quick, clear responses. Built with strong privacy and role-based controls, Sofia supports everyday decision making for study teams without compromising data security or the integrity of the study blind.

Recognized for innovation

Suvoda’s approach earned continued recognition in 2025, including a new patent for its platform architecture, bringing its total to five. Everest Group also named Suvoda a Leader in its RTSM PEAK Matrix® assessment. Across its portfolio, Suvoda released enhancements that improve transparency, data quality, and ease of use, reflecting its ongoing focus on practical innovation that supports real-world trial operations.

Positioned for continued growth in 2026

The company anticipates continuing its strong growth in 2026 as pharmaceutical sponsors and CROs increasingly look for unified platforms that reduce trial complexity while supporting exceptional patient and site experiences.

“We spent 2025 not only merging two companies, but unifying our technologies, our people, and our mission,” Wanninayake said. “That foundation positions us to deliver even greater value in 2026 and beyond. We’re ready to support sponsors and sites to meet more of their clinical trial needs and help patients move through their studies with ease and confidence.”

About Suvoda

Suvoda is a global clinical trial technology company with a market-leading, real-time software platform that empowers sponsors and CROs to make confident decisions and sites and patients to take calm, controlled action. Suvoda delivers interconnected, action-driven software solutions and industry-leading services and support, so that even in the most time-sensitive, mission-critical moments, life-changing studies keep moving forward. Headquartered outside Philadelphia, Suvoda also maintains offices in Portland, OR, Barcelona, Spain, Bucharest and Iasi, Romania, and Tokyo, Japan. The company maintains customer satisfaction scores that consistently exceed the technology industry average, contributing to the company being selected by trial sponsors and CROs to support more than 2000 trials across more than 95 countries. Suvoda recently merged with Greenphire, a leading provider of clinical trial financial management and patient support tools. To learn more, visit suvoda.com and follow Suvoda on LinkedIn.

CONTACT: 
Robin Abadía 
Director, External Communications 
marketing@suvoda.com

Logo – https://laotiantimes.com/wp-content/uploads/2026/01/suvoda_updated_logo.jpg

Basecamp Research launches world-first AI models for programmable gene insertion

  • The breakthrough tackles a longstanding challenge in genetic medicine with the goal of developing a new generation of curative cell and gene therapies.
  • Developed in collaboration with NVIDIA by training the largest evolutionary AI models on a new, globally collected dataset, accelerated by NVIDIA BioNeMo.
  • The same versatile model also helped design novel antimicrobial peptide molecules with a 97% lab-confirmed success rate, including candidates that appeared highly potent against multidrug-resistant “superbugs.”
  • Basecamp Research also adds NVentures as an investor ahead of Series C round following deep technical collaboration on EDEN models.

LONDON and CAMBRIDGE, Mass., Jan. 12, 2026 /PRNewswire/ — Basecamp Research, a frontier AI lab harnessing evolution to design new medicines, today announced the first AI models capable of programmable gene insertion, offering a new way to replace faulty genes and reprogram cells for therapeutic use. Trained in collaboration with NVIDIA, these models are driving the development of a new generation of treatments for cancer and inherited diseases. In parallel, Basecamp Research secured an investment from NVentures (NVIDIA’s venture capital arm) in its pre-Series C round following years of close technical collaboration, which will help the company to accelerate its research and development efforts.

“We believe we are at the start of a major expansion of what’s possible for patients with cancer and genetic disease,” said John Finn, Chief Scientific Officer at Basecamp Research. “By using AI to design the therapeutic enzyme, we hope to accelerate the development of cures for thousands of untreatable diseases, potentially transforming millions of lives.”

Programmable Gene Insertion

Programmable gene insertion – placing large therapeutic DNA sequences at precise locations in the human genome – has been a central goal in genetic medicine for decades. Existing CRISPR-based approaches can only make small edits and must damage DNA to do so, limiting where and how they can be used. Basecamp Research is the first to demonstrate that AI can design enzymes capable of performing large gene insertion at defined sites in the human genome, opening a long-sought path toward programmable therapies.

Basecamp Research’s AI-Programmable Gene Insertion (aiPGI) platform is powered by EDEN, a new family of evolutionary AI models developed with NVIDIA, trained on BaseData, the company’s proprietary genomics dataset – the largest of its kind. The models learn the language of DNA and patterns of evolution, allowing the algorithms to design new, programmable therapies for cancer and genetic disease.

In lab results published today in a paper co-authored by NVIDIA, Microsoft and leading academics, [link], the EDEN models designed multiple active insertion proteins for 100% of tested disease-relevant target sites in the human genome, requiring only the genomic target site as a prompt and marking a significant step forward in AI model capability.

Basecamp Research has already demonstrated insertion at over 10,000 disease-related locations in the human genome, including therapeutically relevant integration of cancer-fighting DNA into primary human T cells at novel safe-harbour sites. This produced CAR-T cells that show strong killing of cancer cells, showing over 90% tumour-cell clearance in laboratory assays.

AI-Designed Molecules To Fight “Superbugs”

In another key frontier therapeutic design task targeting the global drug-resistance crisis, the same model proved its versatility by designing a focused library of novel antimicrobial peptides (AMPs) – small proteins with the potential to kill harmful bacteria – with 97% of candidates demonstrating confirmed activity in laboratory tests. In a collaboration with University of Pennsylvania scientists led by Prof. César de la Fuente, the top-performing AMPs showed high potency against critical-priority, multidrug-resistant pathogens, offering a powerful new tool in the fight against dangerous “superbugs.”

Breakthrough powered by unique data & frontier AI models

The EDEN models that power aiPGI were trained on over 10 trillion tokens of evolutionary DNA from more than one million newly-discovered species. This data was collected over five years from over 150 locations across 28 countries and five continents as part of a novel data collection strategy pioneered by the company, published in June 2025.

The largest EDEN model was trained on 1.95×1024 FLOPS of compute on a cluster of 1,008 NVIDIA Hopper GPUs and accelerated with libraries from NVIDIA BioNeMo, making it comparable in scale to GPT-4 class models and placing it among the most computationally intensive biological models ever reported.

Therapeutic assets in development

These capabilities underpin Basecamp Research’s emerging pipeline of cell and gene therapies, opening the path to treatments that are more precise, predictable and personalised than those available today. The company’s goal is to develop potentially curative therapies across a range of cancer and genetic disease indications, powered by continued improvements to BaseData, the EDEN models and aiPGI.

About Basecamp Research
Basecamp Research is dedicated to solving major challenges in the life sciences by exploring Beyond Known Biology. The company builds frontier AI models using BaseData, the world’s largest ethically-sourced and globally representative biological dataset. Basecamp Research collects and curates its own biological data through partnerships with more than 152 organizations in 28 countries, giving its AI access to genetic diversity that doesn’t exist for models trained on public database sources. This allows Basecamp Research to design novel protein sequences and biological systems that can accelerate therapeutic research and development.

Basecamp Research partners with biopharma companies and academic institutions worldwide, and its work has been recognized with honors including Fast Company’s Top 10 Most Innovative Companies in Biotech and the FT-backed Sifted AI100 list of Europe’s leading AI startups. Learn more at basecamp-research.com.

BaseData, Beyond Known Biology, EDEN-GLM and aiPGI are brand names and technologies of Basecamp Research.

Relativity Launches aiR for Case Strategy, Bringing Generative AI to Case Intelligence

News Summary:

  • Relativity’s generative AI case intelligence solution, aiR for Case Strategy, launched for general availability today.
  • aiR for Case Strategy extracts key facts from evidence and organizes them into clear timelines, summaries and draft work product, empowering lawyers and litigation professionals to construct the story of their case or investigation with greater speed, confidence and collaboration.
  • Early users have unlocked significant value, surfacing key insights sooner, pulling facts together up to 70% faster and freeing thousands of hours of attorney time for high-impact work.

CHICAGO, Jan. 12, 2026 /PRNewswire/ — Relativity, a legal data intelligence company, today announced the general availability of its generative AI-powered case intelligence solution, Relativity aiR for Case Strategy. Designed with lawyers and litigation professionals in mind, aiR for Case Strategy makes it faster and simpler to develop case narratives, enabling users to auto-extract facts, visualize fact chronologies, accelerate deposition preparation, and create document, witness and transcript summaries.

Relativity
Relativity

“Generative AI is redefining what’s possible in case preparation, empowering legal teams to move from information to insight with greater speed and precision than ever before,” said Phil Saunders, CEO of Relativity. “We’re committed to expanding our case intelligence capabilities because giving our partners and customers a clearer, more complete understanding of their matters sooner enables them to focus on serving their clients, creating greater impact and building narratives that ultimately advance justice.”

Legal teams working across complex disputes often face pressure to understand the facts and issues earlier in the life cycle of a matter. aiR for Case Strategy helps establish a clear factual foundation by revealing key events, illuminating gaps in evidence and highlighting the relationships among people, documents and testimony. This level of context is especially important in disputes and litigation, effectively enabling stronger strategic planning and more confident preparation for witness meetings, interviews and depositions.

Elevating strategic casework from data to decision-making

More than 50 customers have tested aiR for Case Strategy and extracted approximately 600,000 facts through Relativity’s limited general availability program. These early adopters achieved time savings, cost efficiencies, improved collaboration and increased scalability. Tasks that once took hours—sifting through emails, chats and contracts to extract facts, build chronologies and draft summaries—now take minutes. From the outset of a matter, users can uncover the story in their data, shape a case narrative and determine how they want to argue the matter.

“With aiR for Case Strategy, we can see the story behind the evidence much earlier in the process. It helps extract and organize facts into timelines so our teams can quickly turn information into actionable insights,” said Michael Song, Head of GTDocs at Gilbert + Tobin. “That allows our lawyers to spend more time shaping strategy, refining narratives and anticipating challenges, freeing them to focus on the parts of a case that drive the greatest impact.”

Timeline visualizations make it easy to identify gaps or blind spots in the data, helping teams build a complete picture of events. The solution also generates holistic witness summaries that give users a clear view of each key player and support critical decisions about whether a deposition is warranted. Additionally, the solution provides a rich set of interview questions grounded in both the documents and underlying facts, enabling teams to effectively probe each individual’s role in the matter. 

“aiR for Case Strategy dramatically reduces the manual work of extracting facts and building useful timelines in Relativity,” said Martha Louks, Managing Director, Discovery Technology Services, McDermott Will & Emery. “It offers a novel way to eliminate tedious work and allow attorneys to focus on case analysis and strategy.”

Accelerating insight across complex, fast-paced matters

Relativity partner Page One, Inc., used aiR for Case Strategy to support its law firm client on a fast-paced financial services case where large volumes of lengthy deposition transcripts were creating significant pressure on the team. Using the solution to summarize and review 32 transcripts—each 200 to 300-plus pages—the team quickly identified and organized the most important information 70% faster.

“aiR for Case Strategy exceeded expectations by proving not just that it worked, but that it was repeatable, defensible and intuitive,” said Andrew Milauskas, Chief Operating Officer of Page One, Inc. “We went from spending hours per transcript to extracting key facts within minutes. Our confidence grew quickly once we saw that aiR for Case Strategy consistently surfaced the same core insights we would have found manually.”

Transcripts are central to litigation strategy, from depositions to hearings and trials. With aiR for Case Strategy, legal teams can unlock greater clarity from their transcripts through advanced automation and collaboration features. The solution enables users to automatically generate transcript summaries, collaboratively mark up and annotate testimony, and designate key excerpts for trial preparation and presentation. These enhanced capabilities accelerate credibility assessments and empower teams to plot next steps with confidence.

For litigation support professionals, transcript features introduce multi-sync video deposition capabilities, a streamlined workflow for importing depositions and associated files, and exhibit-linking tools that make transcript management more efficient and easier to navigate.

Breaking down silos to build cohesive case stories

Within RelativityOne, aiR for Case Strategy serves as a centralized hub that enables case teams to work from a shared repository of key case intelligence. Teams can move directly from document review into crafting their strategic case story and preparing for investigations, witness examinations, depositions and trial all within one secure, collaborative environment.

“What we’re seeing now with generative AI tools is tighter overlap across teams, reviewers, case teams, and partners working from the same pool of insights,” said Michael Frankel, Counsel at Troutman Pepper Locke. “The silos are breaking down, and everyone can contribute to building the narrative earlier.”

aiR for Case Strategy is currently available in the U.S., the U.K., Australia, Canada, Germany, Switzerland, the Netherlands, Ireland, the UAE, Brazil, South Africa, India, Japan, South Korea, Singapore and Hong Kong, with additional markets to be added over time. The solution is projected to launch in RelativityOne Government in the first half of 2026. To learn more about aiR for Case Strategy, join Relativity on Feb. 19 at 12 p.m. CT for a webinar that walks through how AI is reshaping case strategy to get to the heart of a case faster.

About Relativity
Relativity is a leading legal data intelligence company that builds technology to help users organize data, discover the truth, and act on it. Its extensible, AI-powered cloud platform, RelativityOne, transforms complex data into actionable insights at massive scale for litigation, investigations, regulatory inquiries, data breach responses, and other legal use cases. The world’s largest law firms and corporations, government agencies, and a robust network of channel partners rely on Relativity’s legal AI software to securely surface and manage the most relevant and impactful information in their matters. The company also expands access to technology by providing its platform at no cost to academic institutions through its Relativity Academic program and to organizations supporting pro bono legal work through its Justice for Change initiative.

Contact:
pr@relativity.com